Navigation Links
Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis
Date:7/20/2011

EASTBOURNE, England, July 20, 2011 /PRNewswire/ --


Daval International announced the completion of the treatment period of its randomised, placebo-controlled, double blind Phase II Study, Treating Patients with Bladder Dysfunction with AIMSPRO in Secondary Progressive Multiple Sclerosis (SPMS). Standard clinical measures and assessment scores recorded on patients who have MS, as well as novel biomarkers will be used to investigate safety, efficacy and response to treatment. Daval expects to have the initial results from this trial by the end of the summer of 2011, with secondary and tertiary outcomes (biomarker data) being made available shortly thereafter. The study completion marks more than 10 years of research and development undertaken by Daval with AIMSPRO.

"Daval is extremely delighted to have completed this very complicated study, which is breaking new boundaries in the quest to find a cure for Secondary Progressive Multiple Sclerosis. This study was an important step towards further understanding how much AIMSPRO could really help people with this disease, for which there is currently no cure or therapy and the results are eagerly awaited" said Professor Syed Haq, MBBS, BSc, PhD, DIC, MCRP(UK) - Chief Scientific Officer at Daval.

About the Study

20 patients participated in this randomised, placebo-controlled, double blind, crossover Phase II trial comparing AIMSPRO with a placebo. Subjects in both the placebo and treatment groups of the trial were given the treatment by subcutaneous injection twice weekly for 4 weeks. After a 6 week wash-out period they crossed over to receive 4 weeks of AIMSPRO or placebo. The primary endpoint of the study is the change in average voided volume at weeks 0 to 4 and weeks 10 to 14 respectively. The secondary endpoints of the study are to assess the efficacy of AIMSPRO as a therapeutic agent for SPMS noting the change in average 24-hour frequency; change in visual acuity and colour vision;
'/>"/>

SOURCE Daval International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
2. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Announces Second Quarter Results
7. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
8. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
9. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
10. Mindray Medical International Announces Second Quarter 2008 Results
11. Singapore to hold international pow-wow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Kerr Corporation, ... 10-minute video and additional how-to information about dual arch impressions ... Restorations with Dual Arch Impressions,” the blog entry serves up ... technique and houses a step-by-step demonstration by Dr. David Little ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Summary: Genmab Reports Results for the First Three Months of ... today results for the three month period ended March 31, ... revenues were DKK 167 million (approx. USD 36 million) for ... Genmab recognized,revenues of DKK 80 million (approx. USD 17 million)., ...
... Md., May 28 Novavax, Inc. (Nasdaq:,NVAX) a clinical-stage ... Chief Executive Officer, will be presenting at the,FBR Capital ... on,May 29, 2008 at The Grand Hyatt Hotel in ... company,s strategy, research and development progress. A,link to the ...
... NanoLogix, Inc. (Pink,Sheets: NNLX) a nano-biotechnology company ... personnel will showcase company technology at booth 1304 ... June 1-5 2008. The ASM,meeting is the world,s ... Dr. Sergey Gazenko and CEO Bret Barnhizer.,Exhibition information ...
Cached Biology Technology:Genmab Announces 2008 First Quarter Results 2Genmab Announces 2008 First Quarter Results 3Genmab Announces 2008 First Quarter Results 4NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update 2
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
(Date:7/9/2014)... China challenges the commonly held belief that birds evolved ... fly. The birdlike fossil is actually not a dinosaur, ... a tiny tree-climbing animal that could glide, say American ... Utah, and Alan Feduccia of the University of North ... Ornithology . , The fossil of the Scansoriopteryx ...
(Date:7/9/2014)... is one of the amphibians with the highest distribution ... areas of water where it comes into contact with ... Research carried out by the Spaniard Germn Orizaola from ... of these frogs have developed a defensive response to ... larger bodies if they co-exist with the crayfish. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... are blunt. In an attempt to eradicate tumors, oncologists ... healthy tissue along with the cancerous growths. New research ... bring scientists closer to designing cancer therapeutics that can ... last week in Science Express, follow a ...
... Although sildenafil is best known for promoting erections, it may also ... store more healthy "brown fat" relative to unhealthy "white fat" than ... research published online in The FASEB Journal , ... has been well known as a messenger molecule used by the ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... Genetics Society of America (GSA) Drosophila Research Conference in ... meant to promote the entry of students, postdoctorates and ... basic science community and to encourage the participation of ...
Cached Biology News:Mechanism of mutant histone protein in childhood brain cancer revealed 2Drug for erectile disorder show promise in the treatment of obesity 2
Recombinant Equine IL-6...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: